TScan Therapeutics (NASDAQ:TCRX) versus InflaRx (NASDAQ:IFRX) Head-To-Head Survey

TScan Therapeutics (NASDAQ:TCRX) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Analyst Ratings

This is a summary of current ratings for TScan Therapeutics and InflaRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1	5	2	0	2.12
InflaRx	1	2	5	1	2.67

TScan Therapeutics currently has a consensus price target of $2.67, indicating a potential upside of 803.04%. InflaRx has a consensus price target of $7.43, indicating a potential upside of 342.18%. Given TScan Therapeutics’ higher possible upside, equities analysts clearly believe TScan Therapeutics is more favorable than InflaRx.

Valuation & Earnings

This table compares TScan Therapeutics and InflaRx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32 million	1.94	-$129.77 million	($0.91)	-0.32
InflaRx	$30,000.00	8,252.72	-$51.63 million	($0.58)	-2.90

InflaRx has lower revenue, but higher earnings than TScan Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TScan Therapeutics and InflaRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
InflaRx	N/A	-53.56%	-43.02%

Risk and Volatility

TScan Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500.

Insider & Institutional Ownership

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 6.2% of TScan Therapeutics shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

InflaRx beats TScan Therapeutics on 11 of the 15 factors compared between the two stocks.

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.